Top Global IVD Manufacturer Selects CAPTIS® for AI-Powered Literature Review

21 Aug, 2025

Chicago – August 20, 2025 – Celegence today announced that a Top 10 global in-vitro diagnostics (IVD) manufacturer has chosen its CAPTIS^® platform as their literature review solution, following an in-depth six-month evaluation process against multiple competing technologies.

This decision underscores an accelerating industry-wide shift: regulatory and medical affairs teams are increasingly looking for AI-powered solutions to streamline labor-intensive processes, enhance efficiency, and reduce time-to-compliance.

“By combining our expertise in technology and regulatory operations, and specifically EU MDR & IVDR, we’re spearheading the change this industry needs,” said Punya Abbhi, COO and Co-Founder of Celegence. “CAPTIS^® stands as a testament to our commitment to helping manufacturers realize real efficiencies while keeping their focus on quality and compliance.”

A Client-Centric Trial Process

Unlike typical software trials where users are left to explore platforms independently, Celegence delivered a high-touch, consultative approach from the beginning. The client’s environment was pre-configured based on their workflows; training and AI features were customized for immediate impact at all user levels; and weekly check-ins ensured the client’s feedback directly shaped new platform enhancements throughout the trial.

During the evaluation period, the client witnessed CAPTIS^® innovation cycle in real time as new features rolled out. This showed Celegence’s ongoing commitment to delivering a technology solution that evolves with shifting regulatory industry needs.

Transformative Efficiency Through AI

CAPTIS^® delivered measurable time savings and accuracy improvements through:

Automated Article Retrieval, Deduplication and Traceability
Full Text Snippet Previews from Google Scholar
Dynamic Search Editing & Auto-Updating Search Results
Keyword-Driven Highlights
AI-Powered Data Extraction & Chat
Automated Literature Reports such as PRISMA diagrams and appendices

With automation minimizing manual effort, CAPTIS^® enables literature review teams to reduce workload by more than 30%.

Differentiated by People and Technology

Celegence’s team brings hands-on AI expertise and regulatory knowledge, ensuring clients experience meaningful efficiency gains from day one.

Vision for the Future

This partnership establishes CAPTIS^® as more than a literature reviewing platform; it positions the solution as an integral component of a comprehensive approach to managing the entire regulatory document lifecycle. Through advanced AI capabilities, CAPTIS^® will continue to foster innovation, optimize workflows, and strengthen compliance throughout all phases of regulatory documentation.

About Celegence

Celegence, creator of the CAPTIS^® AI platform, provides a comprehensive suite of tech-empowered regulatory affairs services for pharmaceutical, medical device, and IVD manufacturers seeking to balance the quality, timelines, and cost of their regulatory compliance. Celegence also leverages Dossplorer™, their proprietary advanced eCTD viewer, to improve efficiency in managing submissions and document review. With extensive delivery capabilities and industry expertise, Celegence helps regulatory, and quality teams reduce costs and enhance compliance in a dynamic regulatory environment. Headquartered in the United States, Celegence has offices in Europe and India. For more updates, follow Celegence on LinkedIn or learn more at celegence.com.

For more information, please contact:

Celegence Media Relations
press@celegence.com